The use of tyrosine kinase inhibitors (TKI) has transformed the treatment of clear cell renal cell carcinoma (ccRCC). We have previously published 48 patients with metastatic ccRCC, treated with Sunitinib for 16 weeks and then given a nephrectomy, if feasable. Pretreatment biopsy material was taken for diagnostic purposes. Little translational work on this treated tissue is available. Changes in morphology after TKI therapy are not well documented and the possibility of a ‘regression score’ in treated cancers may aid further therapy.
|Title of host publication||101st Annual Meeting Abstracts, Vancouver Convention Centre, Vancouver, British Columbia, Canada, March 17 – March 23, 2012|
|Publisher||Laboratory investigation; a journal of technical methods and pathology|
|Publication status||Published - 1 Feb 2012|